Metagenomi reports Q2 2026 results, stays on track for MGX-001 hemophilia A IND filing
Company confirms 4Q 2026 IND submission plan for MGX-001, with clinical trials expected to start in 2027 pending clearance, and reports $120.7 million in cash.
SEC filing